Evaluation of WATCHMAN Left Atrial Appendage Occlusion Device in Patients With Atrial Fibrillation Versus Rivaroxaban

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

Also called NCT02549963

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02549963
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
Not reported
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02549963. Randomized; no masking; primary purpose prevention. Start 2015-10 (registry gives no type); primary completion 2017-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of WATCHMAN Left Atrial Appendage Occlusion Device in Patients With Atrial Fibrillation Versus Rivaroxaban
Condition
Stroke
Intervention (Device)
WATCHMAN Left Atrial Appendage Occlusion Device
Intervention (Drug)
Rivaroxaban
Lead sponsor
Shulin Wu (class: other)
Collaborator
Wuhan Asia Heart Hospital (class: other)
Collaborator
Beijing Anzhen Hospital (class: other)
Collaborator
First Affiliated Hospital, Sun Yat-Sen University (class: other)
Collaborator
Second Affiliated Hospital of Guangzhou Medical University (class: other)
Collaborator
The First Affiliated Hospital of Guangzhou Medical University (class: other)
Collaborator
Guangdong Medical College (class: other)
Collaborator
First Affiliated Hospital of Jinan University (class: other)
Collaborator
Nanfang Hospital, Southern Medical University (class: other)

Record details

Record id
cardio:ct-nct02549963
Content hash
357f5b82b59b17424df7eaf8abdde3e39c807e39b770bfa14e41bdd15312150e